[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628652":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":26,"responsibleParty":39,"collaborators":41,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":26,"enrollmentInfo":54,"targetDuration":26,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":70,"whyStopped":26,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":26},{"fullName":5,"class":6},"Universität Münster","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sodium Bicarbonate","EXPERIMENTAL","Experimental: Sodium Bicarbonate 8.4% w\u002Fv Intravenous infusion according to the treatment algorithm targeting a pH\\>7.30",[13],"Drug: Sodium Bicarbonate 8.4% Solution for Injection",{"label":15,"type":16,"description":17,"interventionNames":18},"Balanced crystalloid solution","PLACEBO_COMPARATOR","Placebo: Balanced crystalloid solution Intravenous infusion according to the treatment algorithm targeting a pH\\>7.30",[19],"Drug: Balanced crystalloid solution",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Sodium Bicarbonate 8.4% Solution for Injection","Intravenous infusion according to the treatment algorithm. Infusion starts with 100ml\u002Fhr until a pH of 7.30 - 7.35 and a Base Excess of ≥ 0 is reached. Then, infusion is reduced to 25ml\u002Fhr and maintained for 5 hours. After 5 hours, infusion is titrated to a pH of \\>7.30.",[9],null,{"type":22,"name":15,"description":24,"armGroupLabels":28,"otherNames":26},[15],[30],{"name":31,"affiliation":32,"role":33},"Alexander Zarbock, MD","University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Medicine and Pain Therapy","STUDY_CHAIR",[35],{"name":31,"role":36,"phone":37,"phoneExt":26,"email":38},"CONTACT","+49251-8347255","ESCALATE@ukmuenster.de",{"type":40,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[42],{"name":43,"class":6},"German Research Foundation","100628652","phase-4-sodium-bicarbonate-for-critically-ill-patients-with-metabolic-acidosis-and-acute-kidney-injury-100628652",false,"NCT07464431","Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury","Evaluating the Clinical Effectiveness of Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury (ESCALATE)","ESCALATE","Inclusion Criteria:\n\n1. Adult ≥ 18 years\n2. Critically ill patients (requiring treatment on an ICU or IMC)\n3. Metabolic acidosis, defined as all of the following:\n\n   1. Arterial pH ≤7.25\n   2. PaCO2 \\\u003C 6.5kPa (\\\u003C49 mmHg)\n   3. Standard bicarbonate ≤20 mmol\u002FL\n   4. Standard Base Excess \\\u003C-2\n4. AKI stage 2 or 3 of the KDIGO classification\n5. Written informed consent of the patient or legal representative or authorized representative or emergency inclusion (according to Article 35 EU-Regulation 536\u002F2014)\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding patients\n2. Respiratory acidosis (acute or chronic) \\[dynamic, and if corrected, patient may be reconsidered for the trial\\]\n3. Patients on KRT, or KRT immediately indicated and treating clinician(s) unwilling to defer\n4. Deemed unsuitable for KRT\n5. High output stoma\u002Fileostomy\n6. Percutaneous biliary drainage\n7. End stage kidney failure defined as documented eGFR \\\u003C15ml\u002Fmin\u002F1.73m 2 prior to onset of this acute illness or end stage kidney disease (ESKD) on dialysis\n8. Known renal tubular acidosis\n9. Diabetic ketoacidosis\n10. High anion gap acid poisoning (e.g. polyethylene glycol (PEG), aspirin, methanol)\n11. Symptomatic hypocalcaemia (Ionized calcium \\\u003C1.05 mmol\u002FL)\\[dynamic, and if corrected, patient may be reconsidered for the trial\\]\n12. Hypernatremia (plasma sodium \\>150 mmol\u002FL)\\[dynamic, and if corrected, patient may be reconsidered for the trial\\]\n13. Severe hypokalemia (potassium \\\u003C3.0 mmol\u002FL)\\[dynamic, and if corrected, patient may be reconsidered for the trial\\]\n14. Death perceived as imminent\n15. Known hypersensitivity to sodium bicarbonate or EDTA (Disodiumedetate)\n16. Previously randomized into ESCALATE","ALL","18 Years",{"count":55,"type":56},660,"ESTIMATED","INTERVENTIONAL",[59],"PHASE4","The study investigates whether sodium bicarbonate is able to reduce the occurrence of major adverse kidney events on day 90 (MAKE90) in critically ill patients with metabolic acidosis and acute kidney injury (AKI). While its efficacy in this context has been suggested in a subgroup analysis of the BICAR-ICU trial it has not been confirmed in a double-blinded randomized controlled trial to date.",[62,63,64],"Acute Kidney Injury","Metabolic Acidosis","Critical Illness",[66,67,68,69],"Acute kidney injury","Metabolic acidosis","Critical illness","Sodium bicarbonate","NOT_YET_RECRUITING","2026-04-28",{"date":73,"type":74},"2026-05-05","ACTUAL",{"date":76,"type":56},"2026-05",{"date":78,"type":56},"2028-12",{"name":5,"class":6}]